A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 2, 2009, Pages 169-171

  Zanotti Fregonara, Paolo ^a   Grassetto, Gaia ^b   Hindié, Elif ^c   Rubello, Domenico ^b  

^a DIF   (France)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ANTIBODY TITER; CANCER ADJUVANT THERAPY; DISTANT METASTASIS; ECHOGRAPHY; EDITORIAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MICROMETASTASIS; POSTOPERATIVE CARE; RADIOISOTOPE THERAPY; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

BIOLOGICAL MARKERS; HUMANS; IODINE RADIOISOTOPES; RADIOTHERAPY, ADJUVANT; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 58849142446     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0963-2     Document Type: Editorial

References (19)

1. Park EK, Chung JK, Lim IH, Park DJ, Lee DS, Lee MC, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2008; [Epub ahead of print]. doi: 10.1007/s00259-008-0912-0
2. RC Smallridge SE Meek MA Morgan GS Gates TP Fox S Grebe 2007 Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients J Clin Endocrinol Metab 92 82 87
3. EL Mazzaferri RJ Robbins CA Spencer LE Braverman F Pacini L Wartofsky 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma J Clin Endocrinol Metab 88 1433 1441
4. CA Spencer 2004 Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies J Clin Endocrinol Metab 89 3702 3704
5. P Zanotti-Fregonara E Hindié I Keller M Calzada-Nocaudie JY Devaux 2007 Scintigraphic visualization of glossal thyroid tissue during the follow-up of thyroid cancer patients Clin Nucl Med 32 911 914
6. F Pacini M Schlumberger C Harmer GG Berg O Cohen L Duntas 2005 Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur J Endocrinol 153 651 659
7. EL Mazzaferri RT Kloos 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer J Clin Endocrinol Metab 86 1447 1463
8. G Ronga M Filesi G Ventroni AR Vestri A Signore 1999 Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma Eur J Nucl Med 26 1448 1452
9. M Toubeau C Touzery P Arveux G Chaplain G Vaillant A Berriolo 2004 Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer J Nucl Med 45 988 994
10. D Casara D Rubello G Saladini G Masarotto A Favero ME Girelli 1993 Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables J Nucl Med 34 1626 1631
11. E Hindié D Mellière F Lange I Hallaj C de Labriolle-Vaylet C Jeanguillaume 2003 Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 30 974 981
12. E Hindié P Zanotti-Fregonara I Keller F Duron JY Devaux M Calzada-Nocaudie 2007 Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome Endocr Relat Cancer 14 799 807
13. C Rubino F de Vathaire ME Dottorini P Hall C Schvartz JE Couette 2003 Second primary malignancies in thyroid cancer patients Br J Cancer 89 1638 1644
14. AP Brown J Chen YJ Hitchcock A Szabo DC Shrieve JD Tward 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer J Clin Endocrinol Metab 93 504 515
15. D Rubello D Casara ME Girelli M Piccolo B Busnardo 1992 Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study J Nucl Med 33 1478 1480
16. A Bachelot AF Cailleux M Klain E Baudin M Ricard N Bellon 2002 Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma Thyroid 12 707 711
17. AJ Brendel B Lambert M Guyot R Jeandot H Dubourg P Roger 1990 Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma Eur J Nucl Med 16 35 38
18. P Zanotti-Fregonara A Khoury F Duron I Keller S Christin-Maître T Kiffel 2007 Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 34 541 546
19. S Leboulleux PR Schroeder M Schlumberger PW Ladenson 2007 The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers Nat Clin Pract Endocrinol Metab 3 112 121